| | | EXHIBIT 99.01 |
| | Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com |  |
| | | |
| | Press Release | |
| | | |
30 August 2005
Shire Pharmaceuticals Group plc (the "Company")
The Company announces that it was notified on 26 August 2005 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes, in aggregate 19,287,317 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 3.91 per cent of the issued ordinary share capital of the Company.
V Hemming
Deputy Company Secretary
For further information please contact:
| Investor Relations | | Cléa Rosenfeld (Rest of the World) | | +44 1256 894 160 |
| | Brian Piper (North America) | | +1 484 595 8252 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetics. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
Registered in England 2883758 Registered Office as above
